Matthew Sikora, Associate Professor at University of Colorado Anschutz Medical Campus, shared on LinkedIn:
“They Do exist!
Not a bad way to start the week, with a Notice of Award from NCI.
Really excited to work with Sean Fanning and Julie Hanson Ostrander to develop ‘purpose-built‘ anti-estrogens tailored to the specific pharmacology of the estrogen receptor in lobular breast cancer.
Hoping that this R21 is just the start of a bigger structure>pharmacology>function translational pipeline for ILC research!”
Other articles about breast cancer on OncoDaily.